• Small Molecules
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Investor Fact Sheet

We aim to make a contribution to the evolution of scientific research using our skills, technology and experience to find solutions to the world’s most complex challenges.We harness the power of science and technology to  deliver integrated innovation with pace and efficiency across a diverse range of scientific domains. By providing access to the latest technology and highly trained scientists, underpinned by our values of integrity, excellence and professionalism, our aim is to be a trusted partner for clients seeking to explore the boundaries of science at affordable cost. Our services span the value chain from discovery to the clinic. Beyond the science, our strengths lie in our relentless pursuit of operational excellence; flexible business models; investment in data integrity; and passion for quality. We are proud to have partnerships that are deeply founded and nurtured over the years, delivering a level of commitment and understanding that drives innovation and scientific advances, thus linking our success to that of our clients and the people and patients they serve.

Key Figures (Consolidated, INR Million)

FY17
FY18
FY19
FY20
FY21
Revenue from operations
12,009
14,231
18,256
20,119
21,843
Other Income
707
618
751
816
646
Total income
12,716
14,849
19,007
20,935
22,489
Total expenses
7,933
9,583
12,888
13,940
15,125
EBITDA
4,783
5,266
6,119
6,995
7,364
EBITDA Margin %
37.61
35.46
32.19
33.41
32.70
Depreciation
1,143
1,314
1,642
2,193
2,745
Finance Cost
175
227
323
346
277
Profit Before Tax
3,465
3,725
4,154
4,456
4,342
Tax
592
671
838
794
521
Profit After Tax before exceptional items
2,873
3,054
3,316
3,662
3,821
Exceptional Items (net of tax)
459
228
Profit After Tax after exceptional items
2,873
3,054
3,316
4,121
4,049
Earning per share (INR) (Diluted)
14.55
15.43
16.67
10.35
10.11
Total Paid up Share Capital
2,000
2,000
2,000
4,000
4,000
Bonus Declared
1:1
Net cash from operating activities
3,977
4,462
6,304
6,771
7,012
Net cash from investing activities
-4,691
-3,493
-6,465
-4,284
-6,281
Net cash from financing activities
-808
-787
-724
-2,255
580
Cash and cash equivalents at the end of the year
2,345
2,527
1,652
1,930
3,233
Dividend Per Share (incl. interim and final dividends)
0.50
1.00

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To download, Please share your details

To download, Please share your details